133 related articles for article (PubMed ID: 38597337)
1. Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study.
Alhadab A; Almarhoon A; AlAlwan A; Hammo A
Saudi J Gastroenterol; 2024 Apr; ():. PubMed ID: 38597337
[TBL] [Abstract][Full Text] [Related]
2. Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing.
Argüelles-Arias F; Valdés Delgado T; Maldonado Pérez B; González Antuña J; Castro Laria L
Therap Adv Gastroenterol; 2023; 16():17562848231191670. PubMed ID: 37655058
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentric Observational Study.
Parra RS; Chebli JMF; de Azevedo MFC; Chebli LA; Zabot GP; Cassol OS; de Sá Brito Fróes R; Santana GO; Lubini M; Magro DO; Imbrizi M; Moraes ACDS; Teixeira FV; Alves Junior AJT; Gasparetti Junior NLT; da Costa Ferreira S; Queiroz NSF; Kotze PG; Féres O
Crohns Colitis 360; 2024 Apr; 6(2):otae023. PubMed ID: 38681979
[TBL] [Abstract][Full Text] [Related]
4. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China.
Li P; Wang L; Tang Z; Wang Y; Liu Z; Ge W; Huang Y
Front Pediatr; 2024; 12():1371322. PubMed ID: 38665375
[TBL] [Abstract][Full Text] [Related]
6. The Long-Term Clinical Effectiveness of Ustekinumab in Antitumor Necrosis Factor-Experienced Crohn's Disease Patients.
Altuwaijri M; Hakami L; Alharbi O; Almadi M; Alshankiti S; Aljebreen A; Azzam N
Cureus; 2022 Aug; 14(8):e28536. PubMed ID: 36185868
[TBL] [Abstract][Full Text] [Related]
7. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
[TBL] [Abstract][Full Text] [Related]
9. Long-term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center.
Lim CT; Tay SW; Elangovan S; Ong WC; Lim GH; Salazar E; Chan WPW; Tan MTK
J Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38680014
[TBL] [Abstract][Full Text] [Related]
10. Combination biologic therapy in pediatric inflammatory bowel disease: Safety and efficacy over a minimum 12-month follow-up period.
Wlazlo M; Meglicka M; Wiernicka A; Osiecki M; Matuszczyk M; Kierkus J
J Pediatr Gastroenterol Nutr; 2024 Jul; 79(1):54-61. PubMed ID: 38477410
[TBL] [Abstract][Full Text] [Related]
11. Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease.
Petrov J; Fine S; Alzahrani R; Mohamed G; Al-Bawardy B
J Clin Gastroenterol; 2024 Feb; ():. PubMed ID: 38300529
[TBL] [Abstract][Full Text] [Related]
12. Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
Yerushalmy-Feler A; Pujol-Muncunill G; Martin-de-Carpi J; Kolho KL; Levine A; Olbjørn C; Granot M; Bramuzzo M; Rolandsdotter H; Mouratidou N; Hradsky O; Scarallo L; Matar M; Rimon RM; Rinawi F; Shalem T; Najajra H; de Meij T; Aloi M; Rodríguez-Belvís MV; Alvisi P; Schneider AM; van Rheenen P; Navas-López VM; Kiparissi F; Barrio J; Turner D; Cohen S
J Pediatr Gastroenterol Nutr; 2022 Dec; 75(6):717-723. PubMed ID: 36084231
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease.
Breton J; Kastl A; Hoffmann N; Rogers R; Grossman AB; Mamula P; Kelsen JR; Baldassano RN; Albenberg L
Inflamm Bowel Dis; 2019 Aug; 25(9):1586-1593. PubMed ID: 30715364
[TBL] [Abstract][Full Text] [Related]
14. Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn's Disease: Real-World Data from a German IBD Cohort.
Kubesch A; Rueter L; Farrag K; Krause T; Stienecker K; Hausmann J; Filmann N; Dignass A; Stein J; Blumenstein I
J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31817134
[No Abstract] [Full Text] [Related]
15. Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
Yerushalmy-Feler A; Olbjorn C; Kolho KL; Aloi M; Musto F; Martin-de-Carpi J; Lozano-Ruf A; Yogev D; Matar M; Scarallo L; Bramuzzo M; de Ridder L; Kang B; Norden C; Wilson DC; Tzivinikos C; Turner D; Cohen S
Inflamm Bowel Dis; 2024 Feb; 30(2):159-166. PubMed ID: 37042978
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response.
Heron V; Li Fraine S; Panaccione N; Restellini S; Germain P; Candido K; Bernstein CN; Bessissow T; Bitton A; Chauhan UK; Lakatos PL; Marshall JK; Michetti P; Seow CH; Rosenfeld G; Panaccione R; Afif W
J Can Assoc Gastroenterol; 2022 Oct; 5(5):208-213. PubMed ID: 36196277
[TBL] [Abstract][Full Text] [Related]
17. Experience Using Ustekinumab in Pediatric Patients With Medically Refractory Crohn Disease.
Kim FS; Patel PV; Stekol E; Ali S; Hamandi H; Heyman MB; Verstraete SG
J Pediatr Gastroenterol Nutr; 2021 Nov; 73(5):610-614. PubMed ID: 34415711
[TBL] [Abstract][Full Text] [Related]
18. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
[TBL] [Abstract][Full Text] [Related]
19. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study.
Parra RS; Chebli JMF; Queiroz NSF; Damião AOMC; de Azevedo MFC; Chebli LA; Bertges ER; Alves Junior AJT; Ambrogini Junior O; da Silva BLPS; Lubini M; Bafutto M; Flores C; Vilela EG; Boratto SF; Gasparetti Junior NLT; Steinwurz F; Carvalho NS; Féres O; da Rocha JJR
BMC Gastroenterol; 2022 Apr; 22(1):199. PubMed ID: 35448949
[TBL] [Abstract][Full Text] [Related]
20. P066 Real-World Experience of Ustekinumab in Crohn's Disease Patients With Prior Anti-TNF Therapy at a Tertiary Care Hospital.
Tripathi K; Groudan K; Chalhoub J; Yedla A; Singhania R
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S17. PubMed ID: 37461983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]